ELP化病毒样颗粒疫苗与两种商品化猪圆环病毒2型疫苗的实验攻毒比较评价
研究通过实验攻毒比较ELP化病毒样颗粒(ELP-VLP)猪圆环病毒2型(PCV2)疫苗与商品化灭活圆立佳疫苗及VLP-based Circoflex疫苗的效力。单剂接种后,ELP-VLP组病毒中和抗体和干扰素-γ应答显著强于两种商品疫苗组(p<0.05)。攻毒后仅ELP-VLP组平均日增重显著改善(p<0.05),所有免疫猪血液、鼻分泌物和淋巴结中PCV2载量显著降低(p<0.05),ELP-VLP组尤其明显,且对肺和淋巴组织病理保护更强。结论认为基于临床、免疫、病毒学和病理学评价,ELP-VLP疫苗控制PCV2感染比两种商品疫苗更有效。
要点
- 单剂接种后ELP-VLP组病毒中和抗体和干扰素-γ应答显著强于两种商品疫苗组(p<0.05)。
- 攻毒前所有免疫猪平均日增重均显著改善(p<0.05),攻毒后仅ELP-VLP组平均日增重显著改善(p<0.05)。
- 所有免疫猪血液、鼻分泌物和淋巴结中PCV2载量显著降低(p<0.05),ELP-VLP组尤其明显。
核心结论
- 基于临床、免疫、病毒学和病理学评价,ELP-VLP疫苗控制PCV2感染比两种商品疫苗更有效。
研究设计与样本
- 研究通过实验攻毒比较ELP-VLP PCV2疫苗与商品化灭活圆立佳疫苗及VLP-based Circoflex疫苗的效力。
- 三种疫苗均单剂接种。
主要发现
- 单剂接种后,ELP-VLP疫苗组病毒中和抗体和干扰素-γ应答显著强于两种商品疫苗组(p<0.05)。
- 攻毒前所有免疫猪平均日增重显著改善(p<0.05)。
- 攻毒后仅ELP-VLP免疫猪平均日增重显著改善(p<0.05)。
- 所有免疫猪血液、鼻分泌物和淋巴结中PCV2载量显著降低(p<0.05),ELP-VLP免疫猪尤其明显。
- ELP-VLP疫苗对肺和淋巴组织病理的保护强于两种商品疫苗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Porcine circovirus type 2 (PCV2) is an economically important swine pathogen and vaccination is the primary tool for the disease control. Previously, we developed a more cost-effective PCV2 virus-like particle (VLP) vaccine by using ELPylation technology. In the present study, we compared the ELPylated VLP (ELP-VLP) PCV2 vaccine efficacy with commercial inactivated Yuanlijia vaccine and VLP-based Circoflex vaccine by experimental challenge. After one dose of vaccination with the three different vaccines, ELP-VLP vaccine group showed significantly (p < 0.05) stronger virus neutralizing antibody and interferon-γ responses than the two commercial vaccine groups. All vaccinated pigs showed significant (p < 0.05) improvement in average daily weight gain (ADWG) before challenge. After challenge with PCV2, however, only ELP-VLP-vaccinated pigs showed significant (p < 0.05) improvement in ADWG. All vaccinated pigs showed significant (p < 0.05) reductions in PCV2 loads in the blood, nasal secretion and lymph nodes, ELP-VLP-vaccinated pigs in particular. In addition, vaccination with ELP-VLP vaccine provided stronger protection against pulmonary and lymphoid pathologies than that with the two commercial vaccines. Therefore, ELP-VLP vaccine is more effective to control PCV2 infection than the two commercial vaccines based on clinical, immunological, virological and pathological evaluations.
引用
- Li Y, Lin Y, Xin G, et al. Comparative evaluation of ELPylated virus-like particle vaccine with two commercial PCV2 vaccines by experimental challenge. Vaccine. 2020. PMID: 32284270. doi:10.1016/j.vaccine.2020.03.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。